Multicenter Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation and at Risk for Dialysis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 May 2015
At a glance
- Drugs BB 3 (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Angion Biomedica
- 04 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 04 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 06 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2014 to 1 Apr 2015.